Printer Friendly

Human Genome Sciences obtains United States patent.

Human Genome Sciences, Inc. (Rockville, MD) and University of Michigan (Ann Arbor, MI) has patented Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity. (US 6,951,735)
COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Oct 1, 2005
Words:89
Previous Article:Bayer Pharmaceuticals obtains United States patent.
Next Article:Gen-Probe receives FDA approval for West Nile Virus blood screening assay.
Topics:


Related Articles
Who owns indigenous peoples' DNA?
Zyomyx issued pioneering protein chip patent.
U.S. Genomics awarded pioneering patent.
Zyomyx announces issuance of third protein chip patent.
Mobious Genomics patents ultra high speed sequencing technology.
Human Genome Sciences obtains United States patent.
Lexicon granted exclusive license to Cellectis' homologous recombination technology.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters